Jazz Pharmaceuticals plc Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Jazz Pharmaceuticals plc (JAZZ) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $176.26 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-01.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2023-03-01
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, convertible debt with conversion feature for the quarter ending 2020-06-30 was $176.26M.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $176.26M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 3 month | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|---|
| 2020-12-31 | $176.26M 10-K · filed 2023-03-01 | |
| 2020-06-30 | $176.26M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |